You might also like
Arrowhead Pharmaceuticals (ARWR) develops RNA interference (RNAi)-based therapeutics to treat diseases by silencing specific disease-causing genes. The company leverages its proprietary TRiMTM technology to create medicines that target multiple tissue types, offering simplified manufacturing and improved safety. Arrowhead's clinical pipeline spans various therapeutic areas, including cardiovascular, pulmonary, metabolic, and genetic disorders.
- Cardiovascular Disease - Develops olpasiran (formerly AMG 890 or ARO-LPA), targeting lipoprotein(a) and out-licensed to Amgen.
- Hypertriglyceridemia - Advances plozasiran (formerly ARO-APOC3), aimed at reducing triglyceride levels.
- Dyslipidemia - Focuses on zodasiran (formerly ARO-ANG3), addressing lipid metabolism disorders.
- Pulmonary Conditions - Includes ARO-MUC5AC, ARO-RAGE, and ARO-MMP7, targeting mucus overproduction, inflammation, and fibrosis in the lungs.
- Non-Alcoholic Steatohepatitis (NASH) - Develops GSK-4532990 (formerly ARO-HSD, out-licensed to GSK) and ARO-PNPLA3 for liver diseases.
- Alpha-1 Antitrypsin Deficiency (AATD) - Fazirsiran (formerly ARO-AAT), a collaboration with Takeda, addressing genetic liver and lung conditions.
- Chronic Hepatitis B Virus - Daplusiran/Tomligisiran (formerly JNJ-3989, out-licensed to GSK), targeting viral suppression.
- Complement Mediated Diseases - Develops ARO-C3 to address complement system disorders.
- Muscular Dystrophy - Includes ARO-DUX4 and ARO-DM1, targeting genetic muscle disorders.
- Hepatic Expression of Complement Factor B (CFB) - Advances ARO-CFB for complement-related liver conditions.
- Obesity - Develops ARO-INHBE, targeting metabolic pathways associated with obesity.
- Spinocerebellar Ataxia 2 - Focuses on ARO-ATXN2, addressing genetic neurodegenerative disorders.
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Christopher Anzalone ExecutiveBoard | President, Chief Executive Officer, and Director | Christopher Anzalone has been leading Arrowhead Pharmaceuticals as President, Chief Executive Officer, and Director since December 1, 2007, driving the company’s strategic direction in RNA interference therapeutics. Previously, he founded and served as CEO of The Benet Group LLC and was a partner at Galway Partners, LLC. | View Report → | |
James Hamilton Executive | Chief of Discovery and Translational Medicine | James Hamilton has been with ARWR since 2014 and is currently the Chief of Discovery and Translational Medicine, responsible for target discovery and early clinical development. He previously held roles as Medical Director and Head of Corporate Development, and Vice President, Clinical Development at the company. | ||
Kenneth A. Myszkowski Executive | Chief Financial Officer | Kenneth A. Myszkowski is the Chief Financial Officer of Arrowhead Pharmaceuticals, Inc. since 2009, and he has built extensive financial expertise through prior roles at Broadwind Energy, Epcor USA, NanoInk, Delphion, FMC Corporation, Premark International, and Arthur Andersen & Co. | ||
Patrick C. OBrien Executive | Chief Operating Officer and General Counsel | Patrick C. O'Brien has been serving as Chief Operating Officer since July 2022 and as General Counsel since December 2014 at ARWR. |
-
With your current cash position and expected operating expenses, do you anticipate needing additional capital to initiate the cardiovascular outcomes trial (CVOT) for plozasiran, and how might this affect your willingness to partner other assets to maintain a strong balance sheet given the significant increase in operational expenditure?
-
Can you elaborate on the competitive positioning of plozasiran relative to olezarsen in both familial chylomicronemia syndrome (FCS) and severe hypertriglyceridemia (SHTG), particularly in terms of real-world effectiveness and differentiation from existing therapies?
-
Regarding your obesity program with ARO-INHBE, are you envisioning it primarily as a monotherapy or as an add-on therapy to existing treatments like GLP-1 receptor agonists, and what are the potential upside and downside scenarios you anticipate with the upcoming data readouts?
-
Considering the challenge of launching plozasiran for FCS in a largely undiagnosed patient population over the next 2-3 years, how confident are you that revenues will be meaningful during this period, and is this more of an educational launch ahead of targeting the larger SHTG market?
-
Could you provide more details on your decision to restart efforts with zodasiran for homozygous familial hypercholesterolemia (HoFH), including how you assess the magnitude of the commercial opportunity to justify the incremental R&D and commercial investment?
| Customer | Relationship | Segment | Details |
|---|---|---|---|
GlaxoSmithKline (GSK) | Licensing agreements (GSK-HBV, GSK-HSD) | All | FY2022: $120.0 million (~49.3% of total revenue of $243.2 million )<br/>FY2024: $2.7 million (~75% of total revenue of $3.6 million ) |
Horizon Therapeutics | Licensing/collaboration | All | FY2023: $6.7 million (~2.8% of total revenue of $240.7 million ) |
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
Horizon Therapeutics Ireland DAC | 2023 | Amgen completed the acquisition on October 6, 2023, thereby taking over Horizon and its rights to the clinical development and commercialization of HZN-457, a clinical-stage treatment for uncontrolled gout originally in collaboration with Arrowhead Pharmaceuticals. The deal also led to the termination of the Horizon License Agreement with Arrowhead, effective December 21, 2023, marking a strategic repositioning of the HZN-457 program. |
Recent press releases and 8-K filings for ARWR.
- Daniel Apel has been named Chief Financial Officer effective May 13, 2025, succeeding retiring CFO Ken Myszkowski after 16 years of service.
- Mr. Apel, with previous experience at Walgreens Boots Alliance and Bayer, is expected to support the company’s transition from development to commercial stages.
- During the transition, Ken Myszkowski will serve as an adviser through January 31, 2026 to ensure a smooth handover.
- Strategic Collaboration: Arrowhead closed a license and collaboration agreement with Sarepta Therapeutics, securing an upfront payment of $500M/$825M with potential milestone payments totaling over $11B, strengthening its cash position and supporting both partnered and wholly owned assets.
- Regulatory Milestone: The investigational plozasiran NDA for familial chylomicronemia syndrome was accepted by the FDA with a PDUFA action date of November 18, 2025, and an independent commercial launch is planned in 2025.
- Financial Results: Q1 fiscal 2025 results (period ended December 31, 2024) reported revenue of $2.5M and a net loss of approximately $173M.
- Pipeline and Trials: Key near-term value drivers include multiple Phase III studies for plozasiran, ongoing trials in obesity and CNS indications, and potential additional milestone-related capital infusions.
- Cash Strength: Substantial cash inflows from the Sarepta collaboration have positioned Arrowhead with a robust cash runway into 2028.